PlushCare vs Sesame: Clinical Comparison for GLP-1

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlushCare and Sesame both deliver remote GLP-1 prescribing, but they differ fundamentally in provider model, appointment structure, and clinical depth. PlushCare uses subscription-based primary care; Sesame functions as a marketplace connecting patients with independent providers. Neither model alone predicts treatment success—clinical evaluation quality and personalized assessment matter most.

Choosing between platforms requires understanding how your metabolic profile, genetic factors, and health history influence GLP-1 response. PlexusDx bridges this gap by combining provider guidance with precision peptide genetics, helping you make an informed decision about which telehealth model suits your clinical needs and personalization goals.

How PlushCare and Sesame Structure Provider Access Differently

PlushCare assigns you a primary care physician for ongoing relationships; Sesame lets you browse and book independent providers per visit. PlushCare emphasizes continuity; Sesame emphasizes choice and affordability. Both models have trade-offs: continuity supports deeper health history review, while choice allows you to find specialists in GLP-1 management.

Provider qualification standards vary. PlushCare vets physicians through internal credentialing; Sesame allows independent practitioners to list services, creating variability in GLP-1 expertise. Neither platform guarantees advanced metabolic assessment or genetic risk evaluation. Your individual provider's depth of assessment matters as much as the platform's structure.

Clinical Assessment Depth: What to Expect from Each Platform

Quality GLP-1 prescribing requires baseline labs (fasting glucose, HbA1c, lipids), cardiovascular history review, and contraindication screening. Standard telehealth visits may not explore all relevant biomarkers or genetic predispositions that inform medication selection and dosing strategy. Below is a framework for evaluating what each platform typically covers versus what advanced personalization requires.

Assessment Element	PlushCare Typical	Sesame Typical	Advanced Personalization
Initial Visit Duration	30–45 minutes	15–30 minutes	45–60 minutes with specialist
Baseline Lab Review	Often included	Variable; patient may order	Comprehensive metabolic panel + inflammatory markers
Cardiovascular History	Standard screening	Depends on provider	Detailed family history, previous events
Genetic/Metabolic Predisposition	Not typically assessed	Not typically assessed	Peptide pathway genetic testing
Ongoing Provider Continuity	Same physician	Provider varies per visit	Dedicated GLP-1 specialist

Cost, Accessibility, and Hidden Factors in Platform Choice

PlushCare charges monthly subscriptions ($75–$99) plus visit fees; Sesame charges per-visit ($40–$150 depending on provider). Medication cost depends on your pharmacy and insurance, not the platform. Neither covers compounded GLP-1 medications directly—you pay out-of-pocket or use HSA/FSA funds. True affordability includes total visit plus medication expense over time.

Accessibility factors beyond price include appointment wait times, provider responsiveness, and integration with labs. PlushCare's model ensures consistent follow-up; Sesame's marketplace model may delay follow-up if your preferred provider fills up. Neither platform automatically tracks biomarkers or adjusts dosing based on genetic predisposition data, which influences long-term cost-effectiveness.

Safety Considerations and Clinical Eligibility Across Platforms

GLP-1 medications carry genuine safety considerations: pancreatitis risk (rare), thyroid concerns in predisposed individuals, dehydration, and contraindications in personal or family history of medullary thyroid carcinoma. Both PlushCare and Sesame should screen for these; the depth of screening varies by individual provider. Remote assessment cannot replace in-person examination for certain cardiac or GI red flags.

Patients with complex medical histories—prior bariatric surgery, significant kidney disease, concurrent diabetes medication use—benefit from deeper clinical assessment than standard telehealth visits provide. PlexusDx genetic testing can reveal predispositions in GLP1R and other peptide pathways, supporting a more informed conversation with any telehealth provider about your individual risk-benefit profile and optimal dosing strategy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test identifies predispositions in key GLP-1 response pathways (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help provide context for how your metabolism responds to GLP-1 medications. This genetic insight complements whichever telehealth platform you choose, adding a layer of personalization that standard remote assessments typically miss.

The genetic test does not predict your exact medication response or guarantee outcomes; rather, it reveals predispositions that should be interpreted with a qualified healthcare provider. When combined with biomarker data (fasting glucose, HbA1c, metabolic markers) and your clinical history, genetic context supports a more tailored conversation about whether standard-dose or microdose GLP-1 protocols may align better with your biology.

Whether you select PlushCare for continuity or Sesame for provider choice, layering genetic and biomarker insights into your decision strengthens personalization. PlexusDx compounded semaglutide and tirzepatide options (priced $149/mo from licensed 503A pharmacies) pair with genetic testing to support a precision-wellness approach beyond what platform choice alone can deliver.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which platform—PlushCare or Sesame—offers better GLP-1 prescribing quality?

Both can deliver safe, effective GLP-1 prescribing if providers conduct thorough assessments. Quality depends on individual provider expertise and assessment depth, not platform alone. Continuity (PlushCare) supports better follow-up; choice (Sesame) may help you find GLP-1 specialists. Neither guarantees personalized biomarker or genetic integr...

Do PlushCare and Sesame cover compounded GLP-1 medications?

Neither platform directly covers compounded semaglutide or tirzepatide. You can obtain prescriptions from either platform and fill them at licensed 503A compounding pharmacies (PlexusDx partners). Costs vary by compound formulation and pharmacy; expect $149/mo. Insurance coverage is limited; HSA/FSA funds often apply.

What biomarkers should I check before starting GLP-1, regardless of platform?

Essential baseline labs include fasting glucose, HbA1c, lipid panel, liver function, kidney function (eGFR), and pancreatic enzymes (amylase/lipase). Consider inflammatory markers (hsCRP) and thyroid function (TSH, free T4) if family history warrants. Your telehealth provider should order these; some platforms include lab ordering, others requir...

Does genetic testing improve GLP-1 outcomes compared to standard telehealth assessment?

Genetic testing alone does not guarantee better outcomes. However, peptide pathway genetics (GLP1R, GIPR, FTO variants) may help provide context for individual metabolism and help guide provider dosing decisions. Genetic insights should be interpreted with your provider and combined with biomarker data for personalized strategy.

Can I use PlushCare or Sesame prescriptions with PlexusDx compounded medications?

Yes. Either platform can prescribe GLP-1; you fill the prescription at a licensed 503A compounding pharmacy. PlexusDx partners with qualified pharmacies offering compounded semaglutide ($149/mo) and tirzepatide ($249/mo). Genetic testing ($99 add-on or $298 standalone) can support your provider's dosing decisions regardless of wh...

PlushCare vs Sesame: Choosing Based on Clinical Evidence and Biomarker Context